Story perspectives

FDA Halts Elevidys as mRNA Therapies Surge Forward

7/23/2025

29 7

Summary

Story summary

Sarepta Therapeutics halted Elevidys shipments due to FDA concerns regarding patient fatalities.
Moderna is collaborating with IBM to leverage quantum computing for improved mRNA therapies.
Dispatch Bio secured $216 million to advance CAR-T cell therapy targeting solid tumors.
Lovable, an AI coding platform, reached $100 million ARR in just eight months, raising $200 million in Series A funding.

History

Historical Context

The FDA's 2004 mandate for stricter drug regulations followed the withdrawal of Vioxx due to safety issues, reshaping pharmaceutical practices. Recently, Sarepta Therapeutics halted Elevidys shipments amid ongoing scrutiny, emphasizing the agency's commitment to patient safety. This evolution in drug development, highlighted by Moderna's collaboration with IBM, reflects a shift towards innovative therapies while underscoring the necessity for rigorous oversight to prevent past mistakes.

1 of 2

Story summary

Sarepta Therapeutics halted Elevidys shipments due to FDA concerns regarding patient fatalities.
Moderna is collaborating with IBM to leverage quantum computing for improved mRNA therapies.
Dispatch Bio secured $216 million to advance CAR-T cell therapy targeting solid tumors.
Lovable, an AI coding platform, reached $100 million ARR in just eight months, raising $200 million in Series A funding.

1 / 2